1 	|BT| (S (NP (DT The) (NN Tg737) (NN gene)) (VP (VBD investigated) (NP (JJ gross) (NN alteration) (NN series) (NN rodent/human) (NN liver) (NN tumor) (JJ human) (JJ tumorigenic) (NN cell) (NN line)))) |ET| |BS|6:G05.360.340.024.340 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 514:B01.050.150.900.649.865 515:C04.588.274.623|ES| 7:1 9:1 19:1 36:1 94:1 264:1 403:1 691:1 836:1 951:1 1805:1 1806:1 1807:1 1808:1 1809:1
1 	|BT| (S (NP (DT A) (NN Cox) (JJ proportional) (NN hazard) (NN model)) (VP (VBD showed) (NP (NP (NN IFITM3) (NN expression) (JJ independent) (JJ prognostic) (NN factor)) (NP (JJ disease-free) (NN survival) (NN patient) (NN colon) (NN cancer))))) |ET| |BS|12:Z01.542.049 50:M01.643 516:E05.318.740.500.700 517:E01.789.200|ES| 18:1 19:1 69:1 72:1 113:1 115:1 120:1 132:1 185:1 274:1 696:1 883:1 884:1 1810:1 1811:1 1812:1 1813:1
1 	|BT| (NP (NP (NP (DT A) (JJ novel) (NN GSK-3) (NN beta-C/EBP) (JJ alpha-miR-122-insulin-like) (NN growth) (NN factor) (CD 1) (NN receptor) (JJ regulatory) (NN circuitry)) (NP (JJ human) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 259:D12.776.395.240.150.500 518:D08.811.913.696.620.682.725.400.185 519:D05.500.117.875|ES| 19:1 36:1 69:1 98:1 102:1 185:1 186:1 303:1 304:1 891:1 1814:1 1815:1 1816:1 1817:1 1818:1
1 	|BT| (S (NP (DT A) (JJ previous) (NN investigation)) (VP (VBD indicated) (NP (NP (NN ATA) (JJ effective) (VBG inhibiting) (NN growth) (NN breast) (NN cancer)) (NP (RB especially) (NN cell) (NN HER2) (NN overexpression))))) |ET| |BS|41:A11 45:G07.700.320.249 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 122:C14.280.383 225:E05.337 520:C10.228.140.252.190.530.060|ES| 18:1 19:1 23:1 69:1 94:1 102:1 152:1 188:1 345:1 880:1 1497:1 1541:1 1639:1 1819:1 1820:1
1 	|BT| (S (NP (JJ Additional) (NN qRT-PCR) (NN analysis)) (VP (VBD revealed) (S (NP (JJ gradual) (NN elevation) (VBG circulating) (NNS miRNAs)) (-LRB- -LRB-) (NP (FRAG (NP (FW i.e.) (, ,) (NN let-7a) (, ,) (NN let-7f) (, ,) (NN miR-34a) (, ,) (NN miR-98) (, ,) (NN miR-331) (, ,) (NN miR-338) (NN miR-652) (-RRB- -RRB-) (NN progress) (NN hepatocarcinogenesis))))))) |ET| |BS|184:D13.150.650.319 448:E05.393.620.500|ES| 2:1 10:1 14:1 19:1 275:1 661:1 876:1 888:1 900:1 1110:1 1623:1 1821:1 1822:1 1823:1 1824:1 1825:1 1826:1 1827:1 1828:1 1829:1 1830:1 1831:1
1 	|BT| (NP (NP (NN AIM) (: :)) (S (VP (TO To) (VP (VB define) (NP (NP (JJ biological) (NN contribution) (NNP Hras) (NN mouse) (NN hepatocarcinogenesis)) (, ,) (VP (VBN quantified) (S (FW vivo) (NP (NN interaction) (JJ mutant) (NNP Hras) (JJ genetic) (NN alteration)) (ADVP (RB frequently)) (VP (VBN associated) (NP (NP (NN liver) (NN cancer)) (, ,) (PP (VBG including) (NP (NP (NN overexpression) (NP (NN transcription) (NN factor) (NN c-myc) (JJ epidermal) (NN growth) (NN factor) (NN receptor) (NN ligand) (VBG transforming) (NN growth) (NN factor) (NN alpha))) (PRN (-LRB- -LRB-) (NP (NN TGFalpha)) (-RRB- -RRB-))))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 64:D08.811.913.696.620.682.725.400.009.300 167:H01.158.273 170:D27.720.470.480 521:D08.811.277.040.330.300.400.500.600 522:D12.644.276.382.750 523:D12.776.260.676|ES| 2:1 10:1 14:1 18:1 19:1 52:1 102:1 104:1 152:1 169:1 184:1 185:1 186:1 378:1 440:1 455:1 487:1 561:1 618:1 698:1 811:1 828:1 836:1 864:1 900:1 951:1 959:1 1360:1 1772:1 1832:1 1833:1 1834:1 1835:1 1836:1 1837:1
1 	|BT| (S (NP (NN Alteration) (NN Apc) (NN gene)) (VP (VBN shown) (NP (NP (NN play) (JJ important) (NN role)) (JJ PhIP-induced) (JJ IQ-induced) (NN rat) (NN colon) (NN carcinogenesis)))) |ET| |BS|3:C04.557.470.035.215.100 15:F01.829.316.616 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 46:A03.556.124.526.356 79:I03.450.642.693 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700|ES| 9:1 19:1 31:1 113:1 207:1 237:1 238:1 280:1 849:1 902:1 1838:1 1839:1 1840:1
1 	|BT| (NP (NNS Alterations) (NP (NP (NN hMSH2) (NN gene)) (VP (VBN linked) (NP (ADJP (QP (RB approximately) (CD 60)) (NN %)) (JJ hereditary) (JJ nonpolyposis) (NN colon) (NN cancer) (NN case))))) |ET| |BS|18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 524:C04.588.274.476.411.307.190|ES| 9:1 18:1 19:1 113:1 369:1 934:1 1363:1 1841:1 1842:1 1843:1 1844:1 1845:1 1846:1
1 	|BT| (FRAG (SBAR (IN Although) (NP (NP (NP (VBN induced) (NN cell) (NN death)) (VBN regarded) (JJ major) (NN component) (NN p53) (JJ tumor-suppressive) (NN activity)) (, ,) (S (ADVP (RB recently)) (VP (VBD found) (SBAR (S (NP (JJ sustained) (NN p53) (NN activation) (JJ subsequent) (NN DNA) (NN damage)) (VP (VBZ promotes) (NP (JJ inflammation-associated) (NN hepatocarcinogenesis)))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 134:G04.299.139 525:C23.550.470 526:G05.355.180|ES| 2:1 12:1 19:1 37:1 94:1 107:1 177:1 225:1 298:1 399:1 411:1 412:1 462:1 666:1 772:1 900:1 1021:1 1319:1 1521:1 1847:1 1848:1 1849:1
1 	|BT| (NP (NP (NP (NN Amplification) (NN HER2)) (PRN (-LRB- -LRB-) (NP (NP (NN ErbB2)) (, ,) (NP (NN c-Neu))) (-RRB- -RRB-))) (NP (NP (NN proto-oncogene) (NN breast) (NN cancer)) (NP (VBN associated) (JJ poor) (NN prognosis) (JJ high) (NN relapse) (NN rate)))) |ET| |BS|63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 159:I01.880.735.634 163:E01.789 235:G05.360.340.024.340.375.500.791 527:C23.550.291.937|ES| 2:1 10:1 14:1 18:1 19:1 23:1 41:1 169:1 178:1 188:1 544:1 545:1 563:1 1012:1 1705:1 1850:1 1851:1
1 	|BT| (S (NP (NP (NN Androgen) (JJ receptor-induced) (NN tumor) (NN suppressor)) (, ,) (NP (NN KLLN)) (, ,)) (VP (VBZ inhibits) (SBAR (S (NP (NN breast) (NN cancer) (NN growth)) (ADVP (RB transcriptionally)) (VP (VBZ activates) (NP (JJ p53/p73-mediated) (NN apoptosis) (NN breast) (NN carcinoma))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 45:G07.700.320.249 122:C14.280.383 206:G05.360.340.024.340.375.249 528:D12.776.826.750.150|ES| 2:1 7:1 18:1 19:1 23:1 89:1 102:1 301:1 304:1 615:1 700:1 1478:1 1852:1 1853:1 1854:1 1855:1
1 	|BT| (NP (NP (NN Antitumor) (NN function) (NN microRNA-122) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|104:C04.557.470.200.025.255 184:D13.150.650.319|ES| 19:1 33:1 303:1 304:1 1856:1 1857:1
1 	|BT| (S (NP (NN Astrocyte) (JJ elevated) (NN gene-1) (NN c-Myc)) (VP (VBP cooperate) (VP (VBP promote) (NP (NN hepatocarcinogenesis) (NN mouse))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 529:A08.637.200|ES| 19:1 52:1 474:1 679:1 756:1 824:1 900:1 1858:1 1859:1
1 	|BT| (NP (NP (NP (NN BACKGROUND)) (CC &) (NP (NNS AIMS))) (SBAR (: :) (S (S (NP (NNS Mutations) (NN APC) (NN gene)) (VP (VBP result) (VP (VBN increased) (S (NP (NN propensity)) (VP (VB develop) (NP (JJ intestinal) (NN neoplasia))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NP (JJ complete) (NN understanding) (NN mechanism)) (VP (VBG resulting) (NP (NN tumor) (NN formation)))) (VP (VBD remained) (ADJP (JJ elusive))))))) |ET| |BS|8:C04 18:G05.365.590 20:G03.495 21:G05.360.340.024.340.375.249.050 30:Z01.058.290.190.800 31:D08.811.520.224.800 102:C04.588.274.476.411 239:F02.463.188.357|ES| 2:1 7:1 9:1 11:1 19:1 43:1 47:1 101:1 104:1 109:1 162:1 172:1 217:1 384:1 640:1 648:1 777:1 905:1 1046:1 1387:1 1410:1 1777:1 1778:1 1860:1 1861:1
1 	|BT| (S (SBAR (IN Because) (S (NP (NN Notch) (NN signaling) (VBN implicated) (NN colon) (NN cancer) (NN tumorigenesis)) (VP (VBZ protects) (NP (NP (NN cell) (NN apoptosis)) (VP (VBG inducing) (NP (JJ prosurvival) (NN target))))))) (, ,) (VP (VBD hypothesized) (SBAR (S (NP (NP (NN inhibition) (NN Notch) (NN signaling) (NN gamma-secretase) (NN inhibitor)) (PRN (-LRB- -LRB-) (NP (NN GSI)) (-RRB- -RRB-))) (VP (MD may) (NP (VB enhance) (NP (NN chemosensitivity) (NN colon) (NN cancer) (NN cell)))))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 41:A11 43:F01.145.544 69:G02.111.087.800 125:D08.811.277.656.300.032|ES| 2:1 10:1 14:1 18:1 19:1 78:1 89:1 94:1 103:1 113:1 160:1 195:1 256:1 380:1 386:1 491:1 977:1 1690:1 1750:1 1862:1 1863:1 1864:1 1865:1 1866:1 1867:1
1 	|BT| (S (PP (IN By) (NP (JJ immunohistochemical) (NN analysis))) (, ,) (NP (CD 20) (CD 38) (NN case) (JJ undifferentiated) (NN type)) (VP (VBD advanced) (NP (NP (NN stomach) (NN cancer) (NN K-sam)) (JJ positive)) (, ,) (PP (IN whereas) (NP (NP (NN none) (CD 11) (NN case)) (SBAR (S (NP (VBN differentiated) (JJ intestinal) (NN type)) (VP (VBD revealed) (NP (NN K-sam) (NN staining))))))))) |ET| |BS|47:A03.556.124 74:G04.299.151 232:D02.886.030.676.180|ES| 2:1 18:1 19:1 109:1 233:1 275:1 372:1 543:1 661:1 782:1 801:1 803:1 804:1 934:1 997:1 1057:1 1167:1 1605:1 1868:1 1869:1 1870:1 1871:1
1 	|BT| (S (ADVP (RB Collectively)) (, ,) (NP (NN miR-122) (NN depletion)) (VP (VBZ facilitates) (NP (NP (NN cystogenesis) (NN hepatocarcinogenesis) (NN mouse) (NN DEN) (NN challenge)) (VP (VBG up-regulating) (NP (NP (JJ several) (NN gene)) (VP (VBN involved) (NP (NP (NN proliferation)) (, ,) (NP (NN growth) (NN factor) (NN signaling)) (, ,) (NP (NN neovascularization)) (, ,) (NP (NN metastasis))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 69:G02.111.087.800 113:C04.697.650 150:Z01.542.248.960 344:M01.438 530:C23.550.589.500|ES| 2:1 9:1 19:1 52:1 102:1 185:1 195:1 262:1 299:1 774:1 806:1 900:1 1371:1 1613:1 1789:1 1872:1 1873:1 1874:1 1875:1 1876:1 1877:1
1 	|BT| (S (ADVP (RB Collectively)) (, ,) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN loss) (JJ multifunctional) (NN miR-122)) (VP (VBZ contributes) (NP (NP (JJ malignant) (NN phenotype) (NN HCC) (NN cell)) (, ,) (NP (NN miR-122) (JJ mimetic) (RB alone) (NP (NN combination) (JJ anticancer) (NN drug))) (NP (JJ promising) (JJ therapeutic) (NN regimen) (NN liver) (NN cancer))))))))) |ET| |BS|41:A11 52:E02 67:D26 80:G05.695 104:C04.557.470.200.025.255 231:C04.557.465.625.600.380.590 242:A03.620 531:E02.183.750 532:E02.183|ES| 2:1 18:1 19:1 32:1 94:1 101:1 191:1 236:1 241:1 441:1 530:1 541:1 796:1 802:1 836:1 845:1 1517:1 1789:1 1872:1 1878:1 1879:1 1880:1 1881:1
1 	|BT| (NP (NP (NN CONCLUSION)) (: :) (S (NP (DT The) (NN outcome) (NN study)) (VP (VBP represent) (NP (JJ significant) (NN contribution) (JJ current) (NN understanding) (JJ preventive) (NN mechanism) (NN quercetin) (JJ early) (NN stage) (NN liver) (NN cancer) (NN development)) (, ,) (S (VP (VBG demonstrating) (NP (NP (NN addition)) (VP (VBN known) (VP (JJ proapoptotic) (ADJP (ADJP (JJ characteristic)) (, ,) (SBAR (S (NP (NN flavonoid)) (VP (VBZ modulates) (NP (NP (NN expression) (JJ critical) (NN cell) (NN cycle) (NN regulator)) (NN peroxisome) (NN proliferator) (VBD activated) (NN receptor-alpha) (NN activity)))))))))))))) |ET| |BS|239:F02.463.188.357 242:A03.620 353:G04.299.134 473:E01.789.625 533:D03.383.663.283.266.450.284.777 534:D03.383.663.283.266.450 535:H01.770.644.145.431 536:D12.776.826.239.500|ES| 2:1 18:1 19:1 35:1 94:1 104:1 115:1 131:1 135:1 162:1 163:1 175:1 235:1 336:1 399:1 468:1 527:1 547:1 556:1 601:1 606:1 691:1 799:1 825:1 836:1 905:1 1128:1 1129:1 1360:1 1882:1 1883:1 1884:1 1885:1 1886:1 1887:1 1888:1 1889:1
1 	|BT| (S (NP (NN CONCLUSION) (: :)) (NP (DT These) (JJ clinical) (JJ mechanistic) (NN finding)) (VP (VBP indicate) (SBAR (S (NP (NP (NN IFITM3) (JJ direct) (JJ transcriptional) (NN target) (NN KLF4)) (VBN dysregulated) (NP (NN KLF4)) (NN expression)) (VP (VBP lead) (NP (JJ aberrant) (NN IFITM3) (NN expression)) (, ,) (S (ADVP (RB thus)) (VP (VBG contributing) (NP (NN colon) (NN cancer) (NN progression) (NN metastasis))))))))) |ET| |BS|16:C23.550.291.656 86:D01.268.556.435 113:C04.697.650 209:G02.111.087.847|ES| 2:1 18:1 19:1 48:1 84:1 104:1 113:1 115:1 160:1 254:1 559:1 696:1 792:1 806:1 927:1 1259:1 1295:1 1334:1 1479:1 1725:1 1882:1 1890:1 1891:1 1892:1
1 	|BT| (NP (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (JJ Acute) (NN ablation) (NN GSK3beta) (JJ colorectal) (NN cancer) (NN cell)) (VP (VBZ activates) (NP (JJ p53-dependent) (NN apoptosis)))) (SBAR (S (VP (VBZ antagonizes) (NP (NN tumor) (NN growth))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 39:G04.299.139.160 41:A11 45:G07.700.320.249|ES| 7:1 17:1 18:1 19:1 88:1 89:1 91:1 94:1 102:1 104:1 239:1 301:1 794:1 1893:1 1894:1
1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (PRP$ Our) (NN result)) (VP (VB identify) (NP (NP (NP (JJ novel) (NN candidate) (NN mouse) (NN gene)) (, ,) (NP (NN Zfp277)) (, ,)) (SBAR (WHNP (WP$ whose) (NN expression) (NN pattern)) (S (NP (JJ compatible) (NN role)) (VP (VBG mediating) (NP (JJ divergent) (NN effect) (NN Chrm3) (NN Chrm1) (NN gene) (NN ablation) (JJ murine) (JJ intestinal) (NN neoplasia))))))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 47:A03.556.124 102:C04.588.274.476.411 259:D12.776.395.240.150.500 537:G05.360.340.024.340.375|ES| 2:1 9:1 19:1 31:1 52:1 75:1 91:1 101:1 104:1 109:1 115:1 239:1 260:1 627:1 640:1 658:1 761:1 832:1 891:1 919:1 1243:1 1895:1 1896:1 1897:1 1898:1 1899:1
1 	|BT| (S (NP (NN CRC)) (VP (VBD initiated) (NP (NP (NN mutation) (NN tumor) (NN suppressor) (NN gene)) (, ,) (NP (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-))) (, ,) (NP (NN beta-catenin) (NN gene)))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 18:G05.365.590 21:G05.360.340.024.340.375.249.050 23:D12.776.091.249 206:G05.360.340.024.340.375.249|ES| 2:1 7:1 9:1 10:1 11:1 14:1 19:1 34:1 57:1 58:1 59:1 60:1 245:1 700:1 1900:1
1 	|BT| (S (NP (NN CRC) (NN xenograft)) (VP (VBD differed) (NP (NP (NP (NP (NN p53) (NN status)) (PRN (-LRB- -LRB-) (NP (JJ wt) (NN muf)) (-RRB- -RRB-))) (NN microsatellite) (NN instability) (NN phenotype)) (PRN (-LRB- -LRB-) (NP (NP (NN MSI)) (CC +) (NP (JJ altered))) (-RRB- -RRB-))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 80:G05.695 92:E04.936.764 93:A01.941.875 538:C23.550.362.590|ES| 10:1 12:1 14:1 19:1 236:1 245:1 265:1 416:1 693:1 1299:1 1332:1 1901:1 1902:1 1903:1 1904:1
1 	|BT| (NP (NP (JJ Differential) (NN effect) (JJ oncogenic) (NN K-Ras) (NN N-Ras) (NN proliferation)) (, ,) (NP (NN differentiation) (NN tumor) (NN progression) (NN colon))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 16:C23.550.291.656 51:C04.588.274.476.411.307.180 74:G04.299.151 279:D27.888.569.100|ES| 2:1 7:1 13:1 19:1 48:1 75:1 113:1 215:1 299:1 953:1 1905:1 1906:1
1 	|BT| (S (NP (NN Differentiation) (NN therapy) (JJ hepatocellular) (NN carcinoma) (NN mouse) (JJ recombinant) (NN adenovirus)) (VP (VBG carrying) (NP (NN hepatocyte) (JJ nuclear) (NN factor-4alpha) (NN gene)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 52:E02 74:G04.299.151 104:C04.557.470.200.025.255 247:G01.374.676.530 539:D20.215.894.899.024 540:D12.776.260.262 541:C02.256.076 542:B04.280.030|ES| 9:1 19:1 52:1 130:1 303:1 304:1 850:1 1256:1 1420:1 1907:1 1908:1 1909:1 1910:1
1 	|BT| (S (S (NP (JJ Ectopic) (NN expression) (NN miR-155)) (VP (VBD promoted) (NP (NP (NP (NN growth) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN cell)))) (, ,) (IN whereas) (S (NP (NN depletion)) (VP (VBD inhibited) (NP (NN cell) (NN growth))))) |ET| |BS|41:A11 45:G07.700.320.249 104:C04.557.470.200.025.255 107:G05.355.315.202 122:C14.280.383|ES| 2:1 10:1 14:1 19:1 94:1 102:1 115:1 303:1 304:1 305:1 365:1 372:1 441:1 1613:1 1911:1 1912:1
1 	|BT| (S (NP (JJ Ectopic) (NN reactivation) (NN miR-184)) (VP (VBD inhibited) (SBAR (S (NP (NP (NN proliferation) (NP (NP (JJ self-renewal) (JJ triple) (JJ negative) (NN breast) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN TNBC)) (-RRB- -RRB-))) (NN cell) (NN line) (NN vitro)) (VP (VBN delayed) (NP (JJ primary) (NN tumour) (NN formation)))) (VP (VBD reduced) (NP (JJ metastatic) (NN burden) (FW vivo))))))) |ET| |BS|8:C04 20:G03.495 122:C14.280.383 160:C04.588.180.788 543:G04.299.134.220.235|ES| 10:1 14:1 18:1 19:1 23:1 43:1 94:1 216:1 264:1 299:1 305:1 337:1 344:1 365:1 378:1 449:1 452:1 537:1 1011:1 1716:1 1913:1 1914:1 1915:1 1916:1 1917:1
1 	|BT| (NP (NP (JJ Epigenetic) (NN inactivation) (JJ paired) (NN box) (NN gene) (CD 5)) (, ,) (NP (JJ novel) (NN tumor) (NN suppressor) (NN gene)) (, ,) (NP (NP (JJ direct) (NN upregulation) (NN p53)) (NP (VBN associated) (NN prognosis) (JJ gastric) (NN cancer) (NN patient)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 42:G05.355.315.203.374 50:M01.643 163:E01.789 206:G05.360.340.024.340.375.249 249:G05.355.315.800 259:D12.776.395.240.150.500 339:G02.111.087.880|ES| 2:1 7:1 9:1 12:1 18:1 19:1 86:1 120:1 169:1 544:1 578:1 700:1 790:1 891:1 1126:1 1201:1 1314:1 1891:1 1918:1
1 	|BT| (NP (NP (NP (NN ERBB4) (NN alteration)) (NP (NP (NP (DT The) (NN Cancer) (NNP Genome) (NNP Atlas) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (NP (NP (NN data) (NN set) (JJ stratified) (NN survival)) (, ,) (VP (VBN combined) (S (NP (NNP Moffitt) (NNP Cancer) (NNP Center) (NNP Vanderbilt) (NNP Medical) (NNP Center) (NN CRC) (NN expression) (NNS data)) (VP (VBN set) (, ,) (SBAR (S (NP (NN ERBB4) (NN message) (NN level)) (VP (VBD increased) (NP (NN tumor) (NN stage)))))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 96:I03.784 97:V02.302 269:G05.360.340 544:A02.835.232.834.151.500 545:F02.463.425.838 546:V02.150|ES| 2:1 7:1 10:1 14:1 17:1 18:1 19:1 47:1 115:1 164:1 245:1 249:1 274:1 691:1 793:1 951:1 1129:1 1679:1 1919:1 1920:1 1921:1 1922:1 1923:1 1924:1 1925:1 1926:1 1927:1 1928:1
1 	|BT| (S (ADVP (RB Finally)) (, ,) (NP (NN Apo-FHL2) (NN mouse)) (VP (VBD developed) (SBAR (S (NP (NP (NN tumor)) (, ,) (NP (NN FHL2) (NN transgene))) (VP (VBD enhanced) (SBAR (S (NP (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (JJ liver-specific) (NN deletion) (NP (NP (JJ adenomatous) (NN polyposis) (NN coli) (NN gene) (JJ aberrant) (NN Wnt/beta-catenin) (NN signaling) (NN Apc)) (PRN (-LRB- -LRB-) (NP (NN lox/lox)) (-RRB- -RRB-))) (NN animal)))))))))) |ET| |BS|3:C04.557.470.035.215.100 8:C04 11:B01.050.150.900.649.865.635.505.500 19:B01.050 21:G05.360.340.024.340.375.249.050 105:G02.149.115.800.925 242:A03.620 547:G05.360.340.024.340.825 548:D08.811.682.664.500.848 549:G05.355.600.800.320|ES| 2:1 7:1 9:1 10:1 14:1 19:1 46:1 52:1 57:1 58:1 59:1 195:1 280:1 302:1 385:1 412:1 900:1 1059:1 1165:1 1725:1 1799:1 1929:1 1930:1 1931:1 1932:1 1933:1
1 	|BT| (S (NP (JJ Further) (NN study) (NN mechanism) (NN ADCY3) (NN tumorigenesis)) (VP (VBP provide) (NP (NN basis) (JJ new) (JJ molecular) (NN target) (JJ gastric) (NN cancer)))) |ET| |BS|32:C04.697.098.500 33:C04.697.098|ES| 18:1 19:1 78:1 86:1 131:1 160:1 161:1 162:1 330:1 711:1 712:1 1140:1 1934:1
1 	|BT| (S (ADVP (RB Furthermore)) (NP (NP (NN strategy)) (VP (VBN designed) (VP (VB restore) (NP (NN expression) (NN PTEN))))) (VP (MD may) (S (VP (VBG promising) (NP (NP (NN therapy)) (VP (VBG preventing) (NP (NN HCV) (JJ dependent) (NN hepatocarcinogenesis)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 550:B04.450.410|ES| 19:1 115:1 130:1 321:1 334:1 491:1 900:1 1114:1 1517:1 1683:1 1935:1 1936:1 1937:1 1938:1
1 	|BT| (S (NP (NN Germ-line) (NN mutation) (NN APC) (NN gene)) (VP (NN cause) (SBAR (S (NP (NP (JJ adenomatous) (NN polyposis) (NN coli) (PRN (-LRB- -LRB-) (NP (NN APC)) (-RRB- -RRB-))) (, ,) (NP (NN syndrome) (NN patient))) (VP (VBP develop) (NP (CD hundred) (CD thousand) (JJ precancerous) (JJ adenomatous) (JJ colorectal) (NN polyp))))))) |ET| |BS|3:C04.557.470.035.215.100 6:G05.360.340.024.340 21:G05.360.340.024.340.375.249.050 50:M01.643 341:C04.834 551:C04.557.470.035.215 552:G05.365.590.350 553:C23.550.288.500|ES| 2:1 9:1 10:1 11:1 14:1 17:1 19:1 34:1 57:1 58:1 59:1 120:1 647:1 648:1 1130:1 1779:1 1939:1 1940:1 1941:1 1942:1
1 	|BT| (S (S (ADVP (RB Hence)) (, ,) (NP (NN agent)) (VP (VBD prevented) (SBAR (S (NP (NN colon) (NN cancer)) (VP (VBD decreased) (NP (NP (JJ mitotic) (NN index)) (NP (VBN altered) (NN expression) (NN c-myc)))))))) (, ,) (NP (NN p16) (NN p27)) (VP (VBG suggesting) (NP (NP (NN modulation) (NN expression) (NN gene)) (JJ potential) (NNS biomarkers) (JJ chemopreventive) (NN activity)))) |ET| |BS|155:G05.355.310 158:D23.101 203:G05.360.340.024.340.375.249.375 212:E01.370.225.500.385.500|ES| 2:1 9:1 18:1 19:1 113:1 115:1 202:1 399:1 455:1 693:1 720:1 721:1 728:1 827:1 1009:1 1124:1 1269:1 1313:1 1943:1 1944:1 1945:1 1946:1
1 	|BT| (S (NP (JJ Hepatic) (NN loss) (NN miR-122)) (VP (VBZ predisposes) (NP (NN mouse) (JJ hepatobiliary) (NN cyst) (JJ hepatocellular) (NN carcinoma)) (PP (IN upon) (NP (NN diethylnitrosamine) (NN exposure))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 554:D02.654.442.200 555:C04.182|ES| 19:1 32:1 52:1 303:1 304:1 1789:1 1947:1 1948:1 1949:1 1950:1 1951:1 1952:1 1953:1
1 	|BT| (S (NP (NNP Hepatitis) (NNP C) (JJ virus-induced) (NN up-regulation) (NN microRNA-155)) (VP (VBZ promotes) (NP (NN hepatocarcinogenesis) (VBG activating) (NN Wnt) (NN signaling)))) |ET| |BS|69:G02.111.087.800 184:D13.150.650.319 249:G05.355.315.800 339:G02.111.087.880 550:B04.450.410|ES| 19:1 195:1 298:1 877:1 896:1 900:1 1954:1 1955:1 1956:1 1957:1 1958:1
1 	|BT| (S (NP (NN Hepatocarcinogenesis)) (VP (VBD induced) (NP (NN diethylnitrosamine) (JJ hepatic) (NN deletion) (NN PTEN)))) |ET| |BS|306:G05.355.600.800 554:D02.654.442.200|ES| 19:1 412:1 838:1 1059:1 1936:1 1952:1 1959:1
1 	|BT| (NP (NP (ADJP (RB Here) (VBN studied)) (NN role) (NN HNF4alpha) (NN mechanism) (NN deregulation) (NN Cdx2) (NN colon) (NN cancer))) |ET| |BS|15:F01.829.316.616|ES| 18:1 19:1 31:1 113:1 123:1 162:1 213:1 400:1 401:1 402:1
1 	|BT| (S (ADVP (RB Here)) (, ,) (VP (VBD investigated) (NP (NP (JJ molecular) (NN mechanism)) (VP (VBG underlying) (NP (JJ oncogenic) (NN cooperation) (NN c-Myc) (NN E2F1) (NN relationship) (JJ human) (NN liver) (NN cancer)))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 279:D27.888.569.100|ES| 2:1 18:1 19:1 36:1 161:1 162:1 223:1 400:1 403:1 435:1 824:1 836:1 953:1 1960:1 1961:1
1 	|BT| (S (NP (JJ Heterozygous) (NN disruption) (NN PTEN)) (VP (VBZ promotes) (NP (NP (JJ intestinal) (NN neoplasia) (NN APCmin)) (: /) (NP (CC +) (NP (NN mouse)) (: :) (NP (NN role))) (NP (NN osteopontin))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 102:C04.588.274.476.411 157:G05.380.383 350:D12.644.276.374.625|ES| 19:1 31:1 52:1 104:1 109:1 298:1 640:1 1160:1 1602:1 1936:1 1962:1 1963:1
1 	|BT| (S (NP (NN HNF4alpha) (NN Cdx2)) (ADVP (RB also)) (VP (VBD exhibited) (NP (JJ comparable) (VBN deregulated) (NN pattern) (JJ human) (NN CRC)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400 175:J01.897.280.500.269|ES| 5:1 19:1 36:1 123:1 213:1 245:1 260:1 609:1 1964:1 1965:1
1 	|BT| (S (ADVP (RB However)) (, ,) (NP (NP (NP (NN effect) (NN HNF4alpha) (NN cancer) (NN stem) (NN cell)) (PRN (-LRB- -LRB-) (NP (NNS CSCs)) (-RRB- -RRB-))) (NP (NP (NN treatment) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN HNF4alpha)) (VP (VBD reported))) |ET| |BS|52:E02 104:C04.557.470.200.025.255 332:A11.872.650 556:C11.768.175|ES| 2:1 10:1 14:1 18:1 19:1 75:1 94:1 123:1 303:1 304:1 433:1 441:1 546:1 993:1 1106:1 1966:1
1 	|BT| (S (ADVP (RB However)) (, ,) (SBAR (IN whether) (S (NP (NN up-regulation) (NN DLGAP5)) (VP (VBZ contributes) (NP (NN hepatocarcinogenesis))))) (VP (VBZ remains) (ADJP (JJ unclear)))) |ET| |BS|142:I01.880.604|ES| 2:1 19:1 221:1 433:1 442:1 443:1 845:1 896:1 900:1 1191:1
1 	|BT| (S (PP (IN In) (NP (NN aggregate))) (, ,) (VP (VBP conclude) (NP (NP (NP (NN Let-7) (NN depletion) (NN drive) (NN stem) (NN cell) (NN phenotype)) (NN development) (JJ intestinal) (NN cancer)) (, ,) (PP (ADVP (RB primarily)) (IN via) (NP (NN Hmga2)))))) |ET| |BS|66:F01.658.293 80:G05.695 101:C04.588.274.476.411 283:D12.776.260.312.937 308:A11.872 557:D02.241.081.069.600.150|ES| 2:1 18:1 19:1 35:1 94:1 109:1 181:1 236:1 244:1 596:1 1106:1 1613:1 1967:1 1968:1 1969:1 1970:1 1971:1
1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN loss) (NN PTEN) (NN dysregulation)) (VP (VBG transforming) (NP (NP (NN growth) (NN factor) (NN beta) (NN signaling)) (VP (VBN considered) (S (NP (JJ involved) (NN rat) (NN hepatocarcinogenesis) (JJ early) (NN stage))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 69:G02.111.087.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 503:D12.644.276.374.687|ES| 2:1 19:1 32:1 102:1 185:1 195:1 244:1 774:1 849:1 900:1 1061:1 1128:1 1129:1 1202:1 1284:1 1772:1 1936:1 1972:1
1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN MiR-7) (JJ novel) (NN miRNA) (NN tumor) (JJ suppressive) (NN function) (NN colon) (NN cancer)) (VP (VBG targeting) (NP (JJ oncogenic) (NN YY1)))) |ET| |BS|8:C04 184:D13.150.650.319 258:D12.776.260.235.875 259:D12.776.395.240.150.500 279:D27.888.569.100|ES| 2:1 7:1 18:1 19:1 33:1 113:1 244:1 616:1 840:1 879:1 891:1 953:1 1284:1 1973:1 1974:1
1 	|BT| (NP (NP (PP (IN In) (NP (NN conclusion))) (, ,) (NP (S (VP (VBG finding) (S (VP (VBP indicate) (SBAR (S (NP (NN miR-375) (NN target) (NN AEG-1) (NN HCC)) (VP (VBZ suppresses) (NP (NN liver) (NN cancer) (NN cell) (NN growth)) (ADVP (FW vitro) (FW vivo))))))))) (, ,) (NP (NN highlight) (JJ therapeutic) (JJ potential) (NN miR-375) (NN HCC) (NN treatment))))) |ET| |BS|41:A11 45:G07.700.320.249 52:E02 104:C04.557.470.200.025.255 262:A11.436.348|ES| 2:1 18:1 19:1 94:1 102:1 160:1 216:1 244:1 378:1 441:1 541:1 546:1 686:1 827:1 836:1 927:1 1284:1 1479:1 1675:1 1975:1 1976:1
1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN overexpression) (NN PPARgamma1) (NN gene)) (VP (VBZ exerts) (NP (NP (JJ beneficial) (NN effect)) (VP (VBG attenuating) (NP (NN atherosclerosis) (NN progression))))) (VP (VBZ stabilizes) (NP (JJ vulnerable) (NN plaque)))) |ET| |BS|6:G05.360.340.024.340 16:C23.550.291.656 511:C14.907.137.126.307 513:C14.907.137.126 558:C23.300.821|ES| 2:1 9:1 19:1 48:1 75:1 152:1 244:1 984:1 1284:1 1803:1 1804:1 1977:1 1978:1 1979:1 1980:1 1981:1
1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NNS data)) (VP (VBP indicate) (SBAR (S (NP (NN LHX4)) (VP (MD may) (VP (VB act) (NP (JJ potential) (NN tumor) (NN suppressor) (NN hepatocarcinogenesis)) (, ,) (S (VP (VBG suggesting) (S (VP (VBG targeting) (NP (NN LHX4))))))))))) (VP (VBP downregulate) (SBAR (S (NP (NN AFP)) (VP (MD might) (NP (JJ therapeutic) (NN implication))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 81:E02.095.465.425.400.330.050.400 206:G05.360.340.024.340.375.249|ES| 2:1 7:1 19:1 85:1 244:1 246:1 491:1 508:1 541:1 616:1 700:1 793:1 798:1 827:1 900:1 1009:1 1196:1 1284:1 1479:1 1982:1
1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN study)) (VP (VBP show) (SBAR (S (NP (NN TS) (NN gene) (NN expression) (NN pretreatment) (NN biopsy)) (VP (VBZ predicts) (NP (NN response) (JJ local) (JJ rectal) (NN cancer) (JJ neo-adjuvant) (JJ 5-FU-based) (NN chemoradiotherapy) (JJ high) (NN percentage))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 154:Z01.058.266.887 155:G05.355.310 333:D01.045 559:E01.370.225.500.384.100 560:D03.383.742.698.875.404 561:E02.186.079.500|ES| 2:1 9:1 18:1 19:1 115:1 131:1 178:1 244:1 429:1 494:1 509:1 1284:1 1751:1 1983:1 1984:1 1985:1 1986:1 1987:1 1988:1 1989:1 1990:1
1 	|BT| (NP (NP (PP (IN In) (NP (VBN damaged) (NN tissue))) (, ,) (NP (NP (JJ combined) (NN loss) (NN RB) (NN p53)) (VBD resulted) (NP (JJ early) (NN lesion) (NN formation)) (, ,) (NP (NP (JJ aggressive) (NN tumor) (NN progression)) (, ,) (NP (NP (NN gene) (NN expression) (NN signature)) (NP (JJ histologic) (JJ characteristic) (JJ advanced) (JJ human) (JJ hepatocellular) (NN carcinoma))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 16:C23.550.291.656 20:G03.495 98:A10 104:C04.557.470.200.025.255 162:F01.145.126.125 384:G02.111.087.847.750 562:F01.510|ES| 2:1 7:1 9:1 12:1 19:1 32:1 36:1 43:1 48:1 115:1 164:1 244:1 272:1 303:1 304:1 336:1 538:1 594:1 997:1 1128:1 1131:1 1209:1 1230:1 1991:1 1992:1
1 	|BT| (FRAG (PP (IN In) (NP (NP (NP (NN azoxymethane)) (PRN (-LRB- -LRB-) (NP (NN AOM)) (-RRB- -RRB-))) (NN model) (NN colon) (NN cancer))) (, ,) (NP (NP (NN addition) (NN K-ras) (NN mutation)) (, ,) (VP (VBN shown) (S (NP (ADJP (ADJP (JJ wild-type)) (PRN (-LRB- -LRB-) (ADJP (JJ WT)) (-RRB- -RRB-))) (NN Ras)) (VP (VBD activated) (NP (NP (JJ upstream) (NN pathway)) (, ,) (S (VBG including) (, ,) (PP (FW e.g.)) (, ,) (VP (VBG signaling) (NP (NN ErbB) (NN receptor)))))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 69:G02.111.087.800 132:D02.172.080 563:D08.811.913.696.620.682.725.400.009|ES| 2:1 8:1 10:1 14:1 18:1 19:1 34:1 72:1 113:1 163:1 186:1 195:1 237:1 244:1 383:1 468:1 561:1 1121:1 1775:1 1993:1 1994:1 1995:1 1996:1 1997:1 1998:1
1 	|BT| (FRAG (PP (IN In) (NP (NN context))) (, ,) (NP (NP (NP (NN study) (NN p53)) (NP (ADVP (RB therefore)) (NP (JJ obvious) (NN implication) (JJ human) (NN health) (NN performance)))) (, ,) (NP (NP (VBN given) (JJ impaired) (JJ mitochondrial) (NN content) (NN function)) (VBN associated) (NN pathology) (JJ many) (JJ metabolic) (NN disorder)) (NP (JJ ageing) (, ,) (NN type) (CD 2) (NN diabetes)) (, ,) (NP (NN obesity) (NN cancer)) (, ,) (NP (ADJP (RB well) (VBN reduced)) (NN exercise) (NN performance)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 55:B01.050.150.900.649.801.400.112.400.400 564:C18.654.726.500 565:A11.284.430.214.190.875.564 566:G11.427.590.530.698.277 567:G05.360.340.024.340.365 568:C18.452.394.750.149 569:G07.700.320.124 570:C23.550 571:N01.400|ES| 2:1 12:1 18:1 19:1 29:1 33:1 36:1 85:1 131:1 148:1 169:1 218:1 244:1 452:1 543:1 787:1 1040:1 1794:1 1999:1 2000:1 2001:1 2002:1 2003:1 2004:1 2005:1 2006:1 2007:1 2008:1 2009:1 2010:1 2011:1
1 	|BT| (S (PP (IN In) (NP (NN report))) (, ,) (VP (VBP show) (NP (NP (NP (NP (JJ synergistic) (NN action) (NN HBx) (NN p53) (NN mutation) (NN trigger) (JJ progressive) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN formation)) (PP (IN via) (NP (NN src) (NN activation) (NN zebrafish)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 18:G05.365.590 20:G03.495 104:C04.557.470.200.025.255 572:B01.050.150.900.493.200.244.828 573:N05.715.350.200.650|ES| 2:1 10:1 12:1 14:1 19:1 34:1 43:1 225:1 244:1 303:1 304:1 417:1 429:1 441:1 596:1 610:1 2012:1 2013:1 2014:1 2015:1 2016:1 2017:1
1 	|BT| (S (NP (NN Inactivation) (NN APC) (NN gene)) (VP (VBN considered) (S (VP (VBG initiating) (NP (NN event) (JJ human) (JJ colorectal) (NN cancer)))))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 42:G05.355.315.203.374 55:B01.050.150.900.649.801.400.112.400.400|ES| 9:1 11:1 17:1 18:1 19:1 36:1 205:1 1061:1 2018:1 2019:1
1 	|BT| (S (NP (NN Induction) (NN p53)) (VP (VBP render) (NP (JJ ATM-deficient) (NN mouse) (JJ refractory) (NN hepatocarcinogenesis)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 11:B01.050.150.900.649.865.635.505.500|ES| 12:1 19:1 52:1 900:1 2020:1 2021:1 2022:1 2023:1
1 	|BT| (S (NP (NNP Integrated) (JJ transcriptomic) (JJ genomic) (NN analysis)) (VP (VBN defined) (S (NP (NP (JJ distinct) (NN superenhancer) (NN CIMP)) (CC +) (NP (NN colon) (NN cancer))) (VP (VBZ regulates) (NP (NN cMYC) (NN transcription)))))) |ET| |BS|209:G02.111.087.847 268:H01.158.273.180.350 269:G05.360.340|ES| 18:1 19:1 113:1 487:1 603:1 661:1 680:1 910:1 2024:1 2025:1 2026:1 2027:1 2028:1 2029:1
1 	|BT| (S (NP (JJ Intestinal) (NN cancer)) (VP (VBN driven) (SBAR (S (NP (ADJP (RB purely) (NN PTEN-deficiency)) (JJ transgenic) (NN mouse)) (VP (VBD developed) (NP (NP (NN CM) (JJ human) (NN CRC)) (, ,) (NP (NP (NN CM)) (VP (VBN associated) (NP (NNP PTEN) (NNP PRKCZ) (NN readout)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400 66:F01.658.293 87:C18.654.521 99:B01.050.050.136.500 101:C04.588.274.476.411|ES| 2:1 18:1 19:1 36:1 52:1 169:1 204:1 245:1 285:1 920:1 1165:1 1936:1 2030:1 2031:1 2032:1 2033:1 2034:1
1 	|BT| (S (NP (JJ Isogenic) (JJ LKB1-knockdown) (NN breast) (NN cancer) (NN cell) (NN line) (NN pair)) (VP (VBD developed))) |ET| |BS|94:A11.251.210|ES| 18:1 19:1 23:1 94:1 264:1 1165:1 2035:1 2036:1 2037:1
1 	|BT| (S (NP (NN ITF-2)) (VP (VP (VBD disrupted) (PP (IN via) (NP (JJ allelic) (NN loss) (NN chromosome) (NN 18q21)))) (, ,) (SBAR (S (NP (NN ITF-2B) (NN expression)) (VP (VBD lost) (NP (JJ adenoma-carcinoma) (NN transition))))))) |ET| |BS|17:C04.557.470.035 289:A11.284.187 290:G05.365.590.029.530 317:C04.557.470.200.430|ES| 2:1 19:1 32:1 115:1 552:1 596:1 1005:1 1475:1 2038:1 2039:1 2040:1 2041:1 2042:1 2043:1
1 	|BT| (S (NP (JJ K-ras) (NN mutation)) (VP (VBP occur) (ADVP (RB frequently)) (S (NP (NN colon) (NN cancer)) (VP (VBP contribute) (NP (JJ autonomous) (NN growth)))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 45:G07.700.320.249|ES| 18:1 19:1 34:1 102:1 113:1 450:1 698:1 1121:1 2044:1 2045:1
1 	|BT| (NP (NP (JJ Many) (JJ etiological) (NN factor)) (, ,) (PP (VBG including) (NP (NP (NP (NP (NN hepatitis) (NN B) (NN virus) (NN X) (NN antigen)) (PRN (-LRB- -LRB-) (NP (NN HBx)) (-RRB- -RRB-))) (NN p53) (NN mutation)) (, ,) (NP (VBN implicated) (NN hepatocarcinogenesis))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 18:G05.365.590 73:N05.715.350.200|ES| 2:1 10:1 12:1 14:1 19:1 34:1 185:1 561:1 763:1 900:1 929:1 977:1 1030:1 1422:1 2014:1 2046:1 2047:1 2048:1
1 	|BT| (S (NP (NNS Mice)) (NP (JJ heterozygous) (JJ dominant) (NN Min) (NN mutation) (NN Apc) (NN gene)) (VP (VBP develop) (NP (JJ multiple) (JJ intestinal) (NN neoplasia)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 21:G05.360.340.024.340.375.249.050 102:C04.588.274.476.411 157:G05.380.383|ES| 9:1 19:1 34:1 109:1 280:1 583:1 640:1 648:1 649:1 650:1 786:1 2049:1
1 	|BT| (NP (NP (S (NP (NP (NNS Mice)) (VP (VBG lacking) (NP (NP (NN methionine) (NN adenosyltransferase) (NN 1A)) (PRN (-LRB- -LRB-) (NP (NN MAT1A)) (-RRB- -RRB-))))) (VP (VBD reduced) (NP (NN PHB1) (NN expression)))) (, ,) (JJ impaired) (JJ mitochondrial) (NN function)) (, ,) (VP (ADVP (RB spontaneously)) (VB develop) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 574:D08.811.913.225.650|ES| 2:1 10:1 14:1 19:1 33:1 115:1 303:1 304:1 376:1 441:1 452:1 583:1 648:1 1506:1 1792:1 2003:1 2004:1 2050:1 2051:1 2052:1 2053:1
1 	|BT| (S (NP (NN MicroRNA) (NNP 301A)) (VP (VBZ Promotes) (NP (NP (JJ Intestinal) (NN Inflammation) (NNP Colitis-Associated) (NNP Cancer) (NNP Development)) (VP (VBG Inhibiting) (NP (NN BTG1)))))) |ET| |BS|47:A03.556.124 53:C06.405.205.265 122:C14.280.383 184:D13.150.650.319 525:C23.550.470|ES| 19:1 204:1 1919:1 2054:1 2055:1 2056:1 2057:1 2058:1 2059:1 2060:1 2061:1
1 	|BT| (S (NP (NN MicroRNA-122)) (VP (VBZ inhibits) (SBAR (S (NP (JJ tumorigenic) (NN property) (JJ hepatocellular) (NN carcinoma) (NN cell)) (VP (VBZ sensitizes) (NP (NN cell) (NN sorafenib))))))) |ET| |BS|41:A11 104:C04.557.470.200.025.255 122:C14.280.383 184:D13.150.650.319 575:V02.050|ES| 19:1 94:1 303:1 304:1 615:1 841:1 1797:1 1809:1 2062:1 2063:1
1 	|BT| (S (NP (NN microRNA-146a)) (VP (VBZ inhibits) (NP (NP (NN cancer) (NN metastasis)) (VP (VBG downregulating) (NP (NN VEGF) (JJ dual) (NN pathway) (JJ hepatocellular) (NN carcinoma)))))) |ET| |BS|104:C04.557.470.200.025.255 113:C04.697.650 122:C14.280.383 184:D13.150.650.319|ES| 18:1 19:1 303:1 304:1 383:1 615:1 806:1 2064:1 2065:1 2066:1 2067:1
1 	|BT| (NP (NP (NP (NN MicroRNA-21) (JJ potential) (NN link) (JJ non-alcoholic) (NN fatty) (NN liver) (NN disease) (JJ hepatocellular) (NN carcinoma)) (PP (IN via) (NP (NN modulation) (NN HBP1-p53-Srebp1c) (NN pathway))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 104:C04.557.470.200.025.255 184:D13.150.650.319 576:D12.776.260.103.500.750.500 577:C06.552.241.519|ES| 19:1 303:1 304:1 383:1 596:1 827:1 836:1 998:1 1608:1 1945:1 2068:1 2069:1 2070:1 2071:1
1 	|BT| (S (NP (NN MicroRNA-221)) (VP (VBZ governs) (S (NP (NN tumor) (NN suppressor) (NN HDAC6)) (VP (VB potentiate) (NP (JJ malignant) (NN progression) (NN liver) (NN cancer)))))) |ET| |BS|16:C23.550.291.656 30:Z01.058.290.190.800 31:D08.811.520.224.800 184:D13.150.650.319 206:G05.360.340.024.340.375.249 231:C04.557.465.625.600.380.590|ES| 7:1 18:1 19:1 48:1 700:1 802:1 836:1 2072:1 2073:1 2074:1 2075:1
1 	|BT| (S (NP (NN MicroRNA-375) (NN target) (NN AEG-1) (JJ hepatocellular) (NN carcinoma)) (VP (VBZ suppresses) (NP (NN liver) (NN cancer) (NN cell) (NN growth)) (ADVP (FW vitro) (FW vivo)))) |ET| |BS|41:A11 45:G07.700.320.249 104:C04.557.470.200.025.255 184:D13.150.650.319 262:A11.436.348|ES| 18:1 19:1 94:1 102:1 160:1 216:1 303:1 304:1 378:1 686:1 836:1 1976:1 2076:1
1 	|BT| (S (NP (NN MicroRNA-608)) (VP (VBZ inhibits) (NP (NN proliferation) (NN bladder) (NN cancer)) (PP (IN via) (NP (NP (NN AKT/FOXO3a)) (NN signaling) (NN pathway))))) |ET| |BS|69:G02.111.087.800 122:C14.280.383 126:G02.111.087.800 184:D13.150.650.319 378:D08.811.913.696.620.682.700.755|ES| 18:1 19:1 195:1 299:1 383:1 564:1 596:1 615:1 2077:1 2078:1
1 	|BT| (S (NP (NN MicroRNA-7)) (VP (VBZ inhibits) (NP (NP (NN tumor) (NN growth) (NN metastasis)) (VP (VBG targeting) (NP (NN phosphoinositide) (NN 3-kinase/Akt) (NN pathway) (JJ hepatocellular) (NN carcinoma)))))) |ET| |BS|8:C04 45:G07.700.320.249 104:C04.557.470.200.025.255 113:C04.697.650 122:C14.280.383 184:D13.150.650.319 378:D08.811.913.696.620.682.700.755 578:D08.811.913.696.620.550|ES| 7:1 19:1 102:1 303:1 304:1 383:1 615:1 616:1 806:1 2079:1 2080:1 2081:1
1 	|BT| (NP (NP (NN Microsatellite) (NN instability) (NN tool) (NN classification) (JJ gastric) (NN cancer))) |ET| |BS|395:L01.100 538:C23.550.362.590|ES| 18:1 19:1 86:1 831:1 1299:1 1338:1 2082:1
1 	|BT| (S (NP (JJ Microsomal) (NN prostaglandin) (NN E) (NN synthase-1)) (VP (VBN involved) (NP (JJ multiple) (NN step) (NN colon) (NN carcinogenesis)))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356|ES| 19:1 113:1 207:1 649:1 774:1 2083:1 2084:1 2085:1 2086:1 2087:1
1 	|BT| (S (NP (JJ Microsomal) (NN prostaglandin) (NN E) (NN synthase-1)) (VP (VBZ promotes) (NP (NN hepatocarcinogenesis) (NN activation) (JJ novel) (NN EGR1/beta-catenin) (NN signaling) (NN axis)))) |ET| |BS|23:D12.776.091.249 69:G02.111.087.800 259:D12.776.395.240.150.500 579:A02.835.232.834.151.383 580:D12.776.260.158.500|ES| 19:1 195:1 225:1 298:1 891:1 900:1 2083:1 2084:1 2085:1 2086:1 2088:1 2089:1
1 	|BT| (S (NP (NN MiR-122)) (VP (VBZ inhibits) (NP (NP (NN cell) (NN proliferation) (NN tumorigenesis) (NN breast) (NN cancer)) (VP (VBG targeting) (NP (NN IGF1R)))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 122:C14.280.383 183:G04.299.233.750|ES| 18:1 19:1 23:1 78:1 94:1 299:1 615:1 616:1 2090:1 2091:1
1 	|BT| (S (NP (NN MiR-145)) (VP (VBZ modulates) (NP (JJ multiple) (NN component) (JJ insulin-like) (NN growth) (NN factor) (NN pathway) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|104:C04.557.470.200.025.255 581:D12.644.276.937|ES| 19:1 102:1 185:1 303:1 304:1 383:1 606:1 649:1 1021:1 2092:1 2093:1
1 	|BT| (S (NP (NN miR-185)) (VP (VBZ inhibits) (NP (NP (JJ hepatocellular) (NN carcinoma) (NN growth)) (VP (VBG targeting) (NP (NN DNMT1/PTEN/Akt) (NN pathway)))))) |ET| |BS|45:G07.700.320.249 104:C04.557.470.200.025.255 122:C14.280.383 378:D08.811.913.696.620.682.700.755|ES| 19:1 102:1 303:1 304:1 383:1 615:1 616:1 2094:1 2095:1
1 	|BT| (S (NP (NN miR-221)) (VP (VBZ Mediates) (NP (NNP Chemoresistance) (NNP Esophageal) (NNP Adenocarcinoma) (NNP Direct) (NN Targeting) (NN DKK2) (NN Expression)))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700|ES| 19:1 140:1 316:1 1215:1 2096:1 2097:1 2098:1 2099:1 2100:1 2101:1
1 	|BT| (S (NP (NN miR-490-3p)) (VP (VBD exerted) (NP (NP (NN growth)) (: -) (NP (NP (JJ metastasis-suppressive) (NN effect) (JJ gastric) (NN cancer) (NN cell)) (VP (ADVP (RB directly)) (VBG targeting) (NP (NP (NN SMARCD1)) (, ,) (NP (NP (NN SWItch/Sucrose) (NN NonFermentable)) (PRN (-LRB- -LRB-) (NP (NN SWI/SNF)) (-RRB- -RRB-))) (NP (NN chromatin) (NN remodeling) (NN complex) (NN subunit)))))))) |ET| |BS|41:A11 45:G07.700.320.249 113:C04.697.650 582:D09.698.629.305.770 583:D12.776.813|ES| 2:1 10:1 14:1 18:1 19:1 75:1 86:1 94:1 608:1 616:1 621:1 695:1 1346:1 2102:1 2103:1 2104:1 2105:1 2106:1 2107:1 2108:1 2109:1 2110:1
1 	|BT| (S (NP (NN miRNA-548p)) (VP (VBZ suppresses) (NP (NP (NN hepatitis) (NN B) (NN virus) (NN X) (NN protein)) (VP (VBN associated) (NP (NP (JJ hepatocellular) (NN carcinoma)) (VP (VBG downregulating) (NP (NN oncoprotein) (NN hepatitis) (NN B) (JJ x-interacting) (NN protein)))))))) |ET| |BS|104:C04.557.470.200.025.255 184:D13.150.650.319 584:D12.776.624.664|ES| 4:1 19:1 169:1 303:1 304:1 686:1 763:1 929:1 1422:1 2048:1 2065:1 2111:1 2112:1 2113:1
1 	|BT| (FRAG (PP (JJ Molecular) (S (VP (VBG targeting) (NP (NP (NP (NN GSK3beta) (NN overexpression) (NN GSK3beta) (JJ dominant-negative) (NN mutant)) (, ,) (NP (JJ acute-silencing) (NN GSK3beta) (NN RNA) (NN interference)) (, ,)) (VBN reproduced) (NN induction)) (NP (ADJP (RB transcriptionally) (JJ active)) (NP (NN p53) (JJ colorectal) (NN cancer) (NN cell))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 38:Z01.058.290.120.180 40:Z01.542.248.700 41:A11 156:G05.355.315.203.374.790|ES| 2:1 12:1 17:1 18:1 19:1 94:1 152:1 197:1 515:1 516:1 616:1 736:1 811:1 1854:1 1894:1 2114:1 2115:1 2116:1 2117:1
1 	|BT| (S (S (NP (JJS Most) (JJ human) (JJ colorectal) (NN cancer)) (VP (VB arise) (NP (NN accumulation) (NN series) (JJ genetic) (NN alteration) (NN point) (NN mutation)) (PP (IN within) (NP (JJ Ki-ras) (NN p53) (NN gene))))) (, ,) (NP (NN chemical) (NN carcinogen)) (VP (MD may) (VP (VBN implicated) (NP (NN event) (ADJP (RB still) (JJ unidentified)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 18:G05.365.590 55:B01.050.150.900.649.801.400.112.400.400 279:D27.888.569.100 438:G05.365.590.675|ES| 2:1 9:1 12:1 17:1 18:1 19:1 34:1 36:1 205:1 491:1 776:1 864:1 951:1 977:1 1807:1 2118:1 2119:1 2120:1 2121:1 2122:1 2123:1 2124:1 2125:1 2126:1
1 	|BT| (S (S (NP (NN Mouse) (NN strain)) (VP (VBD disrupted) (S (NP (NP (NN sPLA)) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-) (NN gene) (JJ susceptible) (NN Min) (NN phenotype)) (VP (VBP develop) (NP (JJ numerous) (JJ intestinal) (NN polyp))))) (, ,)) (IN whereas) (S (NP (NP (NN mouse) (JJ normal) (NN sPLA)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (VP (VBP develop) (NP (JJ limited) (NN number) (NN polyp))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 80:G05.695 192:D08.811.277.352.100.680.750.937.750 193:C23.300.825.411 444:C23.300.825|ES| 2:1 9:1 10:1 14:1 19:1 52:1 109:1 118:1 148:1 236:1 372:1 646:1 647:1 648:1 650:1 899:1 2039:1 2127:1 2128:1 2129:1 2130:1 2131:1
1 	|BT| (NP (NP (NNS Mutations) (NP (NP (NN APC) (NN gene) (JJ responsible) (JJ familial) (JJ adenomatous) (NN polyposis)) (PRN (-LRB- -LRB-) (NP (NN FAP)) (-RRB- -RRB-))) (NN majority) (JJ sporadic) (JJ colorectal) (NN cancer))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 18:G05.365.590 21:G05.360.340.024.340.375.249.050|ES| 9:1 10:1 11:1 14:1 17:1 18:1 19:1 57:1 58:1 198:1 725:1 854:1 1410:1 2132:1 2133:1
1 	|BT| (NP (NP (NNS Mutations)) (NP (NP (NP (JJ human) (NN DNA) (NN mismatch) (NN repair)) (PRN (-LRB- -LRB-) (NP (NN MMR)) (-RRB- -RRB-))) (NP (NP (NP (NN gene) (NN MLH1) (VBN associated) (JJ hereditary) (JJ nonpolyposis) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NP (NNP Lynch) (NN syndrome)) (, ,) (NP (NN HNPCC))) (-RRB- -RRB-))) (NP (JJ significant) (NN proportion) (JJ sporadic) (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 18:G05.365.590 55:B01.050.150.900.649.801.400.112.400.400 174:G02.111.087.219.220 524:C04.588.274.476.411.307.190|ES| 2:1 9:1 10:1 14:1 17:1 18:1 19:1 36:1 135:1 169:1 513:1 584:1 666:1 723:1 725:1 1294:1 1410:1 1845:1 1846:1 1940:1 2134:1 2135:1 2136:1
1 	|BT| (NP (NNS Mutations) (NP (NP (NN APC) (NN gene) (NN play) (JJ critical) (NN role)) (JJ sporadic) (JJ familial) (NN form) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 18:G05.365.590 21:G05.360.340.024.340.375.249.050 44:F01.829.263 79:I03.450.642.693 189:V02.460|ES| 9:1 11:1 17:1 18:1 19:1 31:1 238:1 630:1 725:1 825:1 854:1 1410:1
1 	|BT| (S (NP (NN NAC1)) (VP (VBZ modulates) (NP (NP (NN sensitivity) (JJ ovarian) (NN cancer) (NN cell) (NN cisplatin)) (VP (VBG altering) (NP (JJ HMGB1-mediated) (JJ autophagic) (NN response)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 390:G04.299.139.399 498:D01.210.375 585:D12.644.276.087.371|ES| 18:1 19:1 94:1 494:1 606:1 607:1 1761:1 1763:1 2137:1 2138:1 2139:1 2140:1
1 	|BT| (S (NP (NN Number) (NN size) (JJ intestinal) (NN tumor)) (ADVP (RB significantly)) (VP (VBD increased) (NP (NN mouse) (NN bearing) (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-) (NN PTEN) (NN mutation)))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 21:G05.360.340.024.340.375.249.050 102:C04.588.274.476.411 455:B01.050.150.900.649.147.890|ES| 7:1 10:1 11:1 14:1 19:1 34:1 47:1 52:1 57:1 58:1 59:1 109:1 124:1 1584:1 1936:1 2141:1 2142:1
1 	|BT| (S (NP (JJ Oncogenic) (NN mutation) (NN K-ras) (NN gene)) (VP (VBP occur) (NP (NP (QP (RB approximately) (CD 50)) (NN %)) (NP (JJ human) (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 18:G05.365.590 55:B01.050.150.900.649.801.400.112.400.400 279:D27.888.569.100|ES| 9:1 17:1 18:1 19:1 34:1 36:1 368:1 369:1 1121:1 1843:1 2044:1 2143:1
1 	|BT| (S (NP (NP (CD One) (JJ common) (JJ rate-limiting) (NN mutation)) (JJ human) (NN CRC)) (VP (VBZ occurs) (NP (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-) (NN gene)))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 21:G05.360.340.024.340.375.249.050 55:B01.050.150.900.649.801.400.112.400.400 194:G05.355.044.250.750|ES| 9:1 10:1 11:1 14:1 19:1 34:1 36:1 57:1 58:1 59:1 245:1 654:1 655:1 656:1 657:1
1 	|BT| (S (NP (PRP$ Our) (NNS data)) (VP (VBP suggest) (NP (JJ important) (NP (NN role) (NN beta2-AR/STAT3/miR) (CD -373) (NN signaling) (NN transformation) (JJ gastric) (NN cancer) (NN cell))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 41:A11 69:G02.111.087.800 82:D12.644.360.024.342.300|ES| 18:1 19:1 31:1 86:1 94:1 195:1 658:1 793:1 796:1 902:1 1384:1 2144:1
1 	|BT| (S (NP (PRP$ Our) (NN finding) (NN support) (JJ mir-660) (NN act) (NN tumor) (NN suppressor) (NN miRNA)) (VP (VBP suggest) (NP (NN replacement) (JJ mir-660) (JJ new) (JJ therapeutic) (NN approach) (NN p53) (JJ wild-type) (NN lung) (NN cancer) (NN treatment)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 52:E02 81:E02.095.465.425.400.330.050.400 181:E04.936.494 184:D13.150.650.319 206:G05.360.340.024.340.375.249 275:C23.888 375:Z01.639.100|ES| 7:1 8:1 12:1 18:1 19:1 246:1 328:1 373:1 541:1 546:1 614:1 658:1 700:1 712:1 796:1 840:1 911:1 927:1 1364:1
1 	|BT| (S (NP (PRP$ Our) (NN finding)) (VP (VBP suggest) (SBAR (S (NP (NN JNK/PTEN) (NN NF-kappaB/PTEN) (NN pathway)) (VP (VBP play) (NP (JJ critical) (NP (NN role) (JJ normal) (NP (JJ intestinal) (NN homeostasis) (NN colon) (NN carcinogenesis))))))))) |ET| |BS|15:F01.829.316.616 33:C04.697.098 46:A03.556.124.526.356 47:A03.556.124 79:I03.450.642.693 152:G07.700.345 210:D12.776.260.600|ES| 19:1 31:1 109:1 113:1 118:1 207:1 238:1 383:1 500:1 658:1 796:1 825:1 927:1 2145:1 2146:1
1 	|BT| (S (NP (NP (PRP$ Our) (VBN integrated) (NN microRNA)) (VP (VBG profiling) (NP (NN approach)))) (VP (VBD identified) (S (NP (NN miR-195-5p)) (ADVP (RB independently)) (VP (VBN associated) (NP (NN prognosis) (NN CRC)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 163:E01.789 184:D13.150.650.319|ES| 19:1 169:1 245:1 271:1 544:1 623:1 658:1 857:1 911:1 2147:1 2148:1 2149:1
1 	|BT| (S (NP (PRP$ Our) (JJ recent) (NN study)) (VP (VB establish) (NP (JJ oncogenic) (NN role) (NP (NP (NNP LSF) (JJ Hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 104:C04.557.470.200.025.255 279:D27.888.569.100|ES| 10:1 14:1 19:1 31:1 131:1 220:1 304:1 441:1 658:1 659:1 953:1 2150:1 2151:1
